Recombinant human tumor necrosis factor

Recombinant human Tumor Necrosis Factor Purification, comparison with conventional columns Ion Exchange disks, Hydro-phobic Interaction disks [72]... 

Because plasma protein and tissue binding influences the amount of drug in each body compartment, the volume of distribution of a drug may be dose dependent (nonhnear). A limited number of binding sites may result in capacity-limited binding in plasma or tissues. Transport from the blood may also be capacity limited. Examples of dose-dependent volume changes show that the volume of distribution of recombinant human tumor necrosis factor (TNF) alpha decreases sharply with a fourfold increase in dose and that the volume of distribution of recombinant human DNase,... 

Murray, K.M., and S.L. Dahl, Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR Fc) in rheumatoid arthritis. Ann Pharmacother, 1997. 31(11) 1335-8. 

Hori K, Ehrke MJ, Mace K, Maccubbin D, Doyle MJ, Otsuka Y, Mihich E. Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity. Cancer Res 1987 47 2793-8. 

SYNS RECOMBINANT HUMAN TUMOR NECROSIS FACTOR a RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-a TNF-a TUMOR NECROSIS FACTOR-a... 

Megyeri P, Abraham CS, Temesvari P, Kovacs J, Vas T, Speer CP (1992) Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neurosci Lett 148 137—140. 

R. Zimmerman, B. Marafino Jr, A. Chan, P. Landre and J. Winkelhake, The Role of Oxidant Injury in Tumour Cell Sensitivity to Recombinant Human Tumor Necrosis Factor in Vivo. Implication for Mechanism of Action, J Immunol 142 (1989) 1405-1409. 

Kuei JH, Tashkin DP.Figlin RA. Pulmonary toxicity of recombinant human tumor necrosis factor. Chest 1989 96(2) 334-8. 

Mittelman A, Puccio C, Gafney E, Coombe N, Singh B, Wood D, Nadler P, Ahmed T, ArUn Z. A phase 1 pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 1992 10(3) 183-90. 

Logan TF, Kaplan SS, Bryant JL, Emstoff MS, Krause JR, Kirkwood JM. Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor. J Immunother 1991 10(2) 84-95. 

Watanabe N, Yamauchi N, Maeda M, Neda H, Tsuji Y, Okamoto T, Tsuji N, Akiyama S, Sasaki H, Niitsu Y. Recombinant human tumor necrosis factor causes regression in patients with advanced malignancies. Oncology 1994 51(4) 360-5. 

Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, Frei E, Kufe DW. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988 80(13) 1039-1044. 

K28. Kreil, E. A., Greene, E., Fitzgibbon, C., Robinson, D. R., and Zapol, W. M. Effects of recombinant human tumor necrosis factor alpha, lymphotoxin, and Escherichia coli lipo-polysaccharide on hemodynamics, lung microvascular permeability, and eicosanoid synthesis in anesthetized sheep. Circ. Res. 65, 502-514 (1989). 

M. Recombinant human tumor necrosis factor-alpha Effects on proliferation of normal and transformed cells in vitro. Science 230, 943-945 (1985). 

D.A. Bellnier (1991). Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. J. Photochem. Photobiol., 8(2), 203-210. 

Hersh EM, Metch BS, Muggia EM et al. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease a summary of the Southwest Oncology Group experience. J Immunother 1991 10 426-431. 

The in vitro release kinetics of numerous growth factors and cytokines were initially determined in phosphate-buffered saline containing azide (PBSA, pH 7.4). Figure 7 depicts the release kinetics of recombinant human tumor necrosis factor-p (rhTNF-p), recombinant human transforming... 

Satomi N, Sakurai A, Haranaka R, Haranaka K (1988) Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor. J Biol Response Mod 7 54-64... 

Etanercept is a recombinant form of human tumor necrosis factor receptor.24 Etanercept provides a therapeutic effect by binding to soluble TNF and preventing its binding with TNF receptors. It is administered subcutaneously once or twice weekly noticeable symptomatic improvement is seen in 1 to... 

Stauber GB, Aggarwal BB (1989) Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937. J Biol Chem 264 3573-3576 Strand S, Hofmann WJ, Hug H, Muller. M., Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1 /Fas) ligand expressing tumor cells - a mechanism of immune evasion Nature Med 2 1361-1366... 

G22. Gray, P. W., Barrett, K Chantry, D., Turner, M., and Feldmann, M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc. Natl. Acad. Sci. U.SA. 87, 7380-7384 (1990). 

Etanercept (Enbrel) is FDA approved for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis. Etanercept is a soluble, recombinant, fully human tumor necrosis factor (TNF) receptor fusion protein consisting of two molecules of the hgand-binding portion of the TNF receptor fused to the Fc portion of IgGl. As a dimeric molecule, it can bind two molecules of TNF. Etanercept binds soluble and membrane-bound TNF, thereby inhibiting the action of TNF. 

Moreland L W, McCabe D P, Caldwell J R, et al. (2000). Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. 27 601-609. 

Gamble, J.R. et al., Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor, Proc Natl Acad Sci U.S.A, 82, 8667, 1985. 

Wing, E J. et al., Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients, Blood, 73, 643, 1989. 

Examples of the early application of recombinant DNA technology in medicine are the development of recombinant human growth hormone human insulin human interferons, thought to have anticancer activity in addition to antiviral activity interleukins (regulatory proteins from lymphocytes that are believed to be important in the treatment of immunodeficiency diseases and cancer) tumor necrosis factor epidermal and bone marrow progenitor cell growth factors and the production of vaccines (Table 12.1). 

Etanercept is a recombinant human soluble tumor necrosis factor-alpha (TNFo ) receptor fusion protein that binds to TNFo and decreases its role in disorders involving excess inflammation. It is approved for subcutaneous use in the treatment of patients with moderate to severe active rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing arthritis and plaque psoriasis. To the adverse reactions mentioned for infliximab, rare reports of congestive heart failure should be added. 

DeLa Cadena, R.A., A. Majluf-Cruz, A. Stadnicki, M. Tropea, D. Reda, IM. Agosti, R.W. Colman, and A.F. Suffredini, Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost, 1998. 80(1) 114-8. 

Eason, ID., S.L. Wee,T. Kawai, H.Z. Hong, I Powelson, M. Widmer, and A.B. Cosimi, Recombinant human dimeric tumor necrosis factor receptor (TNFR Fc) as an immunosuppressive agent in renal allograft recipients. Transplant Proc, 1995. 27(1) 554. 

Weiss, J., Elsbach, P., Shu, C., Castillo, J., Grinna, L., Horwitz, A., Theofan, G. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 90 (1992) 1122-1130. 

---